Human Rhabdomyosarcoma Cell Lines for Rhabdomyosarcoma Research: Utility and Pitfalls
Open Access
- 1 January 2013
- journal article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 3, 183
- https://doi.org/10.3389/fonc.2013.00183
Abstract
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood and adolescence. Despite intergroup clinical trials conducted in Europe and North America, outcomes for high risk patients with this disease have not significantly improved in the last several decades, and survival of metastatic or relapsed disease remains extremely poor. Accrual into new clinical trials is slow and difficult, so in vitro cell line research and in vivo xenograft models present an attractive alternative for preclinical research for this cancer type. Currently, 30 commonly used human RMS cell lines exist, with differing origins, karyotypes, histologies, and methods of validation. Selecting an appropriate cell line for RMS research has important implications for outcomes. There are also potential pitfalls in using certain cell lines including contamination with murine stromal cells, cross-contamination between cell lines, discordance between the cell line and its associated original tumor, imposter cell lines, and nomenclature errors that result in the circulation of two or more presumed unique cell lines that are actually from the same origin. These pitfalls can be avoided by testing for species-specific isoenzymes, microarray analysis, assays for subtype-specific fusion products, and short tandem repeat analysis.This publication has 87 references indexed in Scilit:
- Myogenesis and RhabdomyosarcomaPublished by Elsevier BV ,2011
- Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975‐2005Cancer, 2009
- Molecular Characterization of the Pediatric Preclinical Testing PanelClinical Cancer Research, 2008
- Telomerase Activity in Cell Lines of Pediatric Soft Tissue SarcomasPediatric Research, 2003
- Survival After Relapse in Children and Adolescents With Rhabdomyosarcoma: A Report From the Intergroup Rhabdomyosarcoma Study GroupJournal of Clinical Oncology, 1999
- Characterization of a New Human Embryonal Rhabdomyosarcoma Cell Line, RMS‐GRJapanese Journal of Cancer Research, 1998
- Characterization of malignant mesenchymal cell line (UISO-RS-3) derived from a human rhabdomyosarcoma and inhibition by pharmacologic doses of estrogenIn Vitro Cellular & Developmental Biology - Plant, 1990
- In vitro purging of human rhabdomyosarcoma cells using 4-hydroperoxycyclophosphamide.1990
- The in vitro growth, heterotransplantation, and differentiation of a human rhabdomyosarcoma cell line.1986
- Transformation of Human Embryo Cells With the Use of Cell-Free Extracts of a Human Rhabdomyosarcoma Cell Line (HUS-2): Brief CommunicationJNCI Journal of the National Cancer Institute, 1978